Walvax Biotechnology Co., Ltd. (SHE:300142)

China flag China · Delayed Price · Currency is CNY
12.79
-0.06 (-0.47%)
Apr 29, 2026, 10:25 AM CST
26.13%
Market Cap 20.55B
Revenue (ttm) 2.40B
Net Income (ttm) 285.77M
Shares Out 1.60B
EPS (ttm) 0.18
PE Ratio 72.42
Forward PE 70.41
Dividend 0.16 (1.21%)
Ex-Dividend Date Jan 9, 2026
Volume 43,594,119
Average Volume 45,290,877
Open 11.90
Previous Close 12.85
Day's Range 11.90 - 12.98
52-Week Range 9.85 - 14.65
Beta 0.47
RSI 58.01
Earnings Date Apr 28, 2026

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis c... [Read more]

Sector Healthcare
Founded 2001
Employees 1,981
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300142
Full Company Profile

Financial Performance

In 2025, Walvax Biotechnology's revenue was 2.42 billion, a decrease of -14.29% compared to the previous year's 2.82 billion. Earnings were 177.74 million, an increase of 25.03%.

Financial Statements

News

There is no news available yet.